More Keytruda data to be presented at ASCO meeting

17 May 2019

New Jersey, USA-based Merck & Co (NYSE: MRK) has announced it will present 140 abstracts at the upcoming annual meeting of the Annual Society of Clinical Oncology (ASCO), including on the anti-PD-1 blockbuster Keytruda (pembrolizumab) and Lynparza (olaparib) - in over 25 types of cancer.

Results will include first-time data from the POLO trial evaluating Lynparza, which the firm is developing in collaboration with AstraZeneca (LSE: AZN) in germline BRCA-mutated metastatic pancreatic cancer. These will be presented in a plenary session and in the ASCO press program.

For the multi-billion dollar selling checkpoint inhibitor Keytruda, the firm has five-year survival data in advanced non-small cell lung cancer (NSCLC) from KEYNOTE-001.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK